CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™
Synonyms: CD20cy, CD20 cytoplasmic domain
RECOMBINANT
Clone:
REA1087
Type of antibody:
Primary antibodies, Recombinant antibodies, Releasable antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon

Related products for CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™

MICS (MACSima Imaging Cyclic Staining) applications
Vio R667
Fixation:
FFPE
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
Vio R667
Used products:
130-139-130
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human tonsil. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using CD20 Cytoplasmic Antibody, anti-human, Vio® R667 (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Fixation:
frozen – PFA
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
Vio R667
Used products:
130-139-130
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a human tonsil cryosection fixed with 4% PFA. The section was stained using CD20 Cytoplasmic Antibody, anti-human, Vio® R667 (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Specifications for CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™
Overview
Alternative names

CD20cy, CD20 cytoplasmic domain

Detailed product information

Technical specifications

Clone
REA1087
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies, Releasable antibodies
Species reactivity
human
Antigen
CD20 Cytoplasmic

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD20 Cytoplasmic Antibody, anti-human, REAdye_lease™
Publications
  1. Einfeld, D. A. et al. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 7 (3): 711-717
  2. Lee, E.J. et al. (2017) CD3 and CD20 Immunohistochemical Staining Patterns of Bone Marrow-Infiltrating Malignant Lymphoma Cells. Ann Clin Lab Sci. 47 (2): 136-143
  3. Deans, J. P. et al. (1995) Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J. Biol. Chem. 270 (38): 22632-22638
  4. Vaughan, A. T. et al. (2015) Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J. Biol. Chem. 290 (9): 5424-5437

You have previously chosen International as your location.
What do you want to do?